MCID: SPS057
MIFTS: 42

Spasticity

Categories: Muscle diseases, Neuronal diseases

Aliases & Classifications for Spasticity

MalaCards integrated aliases for Spasticity:

Name: Spasticity 54 29 6

Classifications:



Summaries for Spasticity

NINDS : 54 Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which might  interfere with movement, speech, or be associated with discomfort or pain.  Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. It may occur in association with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders, and often interferes with daily activities.

MalaCards based summary : Spasticity is related to spastic paraplegia 7, autosomal recessive and spastic paraplegia 4, autosomal dominant. An important gene associated with Spasticity is DARS (Aspartyl-TRNA Synthetase). The drugs Acetylcholine and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and testes.

Wikipedia : 76 Spasticity (from Greek, Modern spasmos-, meaning ''drawing, pulling'') is a feature of altered... more...

Related Diseases for Spasticity

Diseases related to Spasticity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 864)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 7, autosomal recessive 34.0 SACS SPG7
2 spastic paraplegia 4, autosomal dominant 33.9 SPAST SPG7
3 spastic paraplegia 15, autosomal recessive 33.9 SPG7 TECPR2
4 spastic paraplegia 13, autosomal dominant 33.8 SPAST WASHC5
5 spastic paraplegia 30, autosomal recessive 33.8 KIF1A WASHC5
6 spastic paraplegia 49, autosomal recessive 33.7 SPG7 TECPR2
7 spastic paraplegia 73, autosomal dominant 33.5 CAPN1 SPG7
8 spastic paraplegia 76, autosomal recessive 33.5 CAPN1 SPG7
9 hereditary spastic paraplegia 33.3 CAPN1 DDHD1 KIF1A SACS SPAST SPG7
10 spastic ataxia 33.2 SACS SPG7
11 spastic paraparesis 33.1 DDHD1 SPAST SPG7 TECPR2
12 primary lateral sclerosis, adult, 1 31.5 SPAST SPG7
13 paraplegia 31.5 DDHD1 KIF1A SPAST SPG7 WASHC5
14 microcephaly 29.5 PCDH12 PLAA SLC1A4 SLC2A1
15 spastic paraplegia 20, autosomal recessive 12.6
16 spastic paraplegia 2, x-linked 12.5
17 spastic paraplegia 17, autosomal dominant 12.5
18 spastic ataxia, charlevoix-saguenay type 12.5
19 spastic paraplegia 11, autosomal recessive 12.5
20 spastic paraplegia 3, autosomal dominant 12.5
21 tropical spastic paraparesis 12.4
22 spastic hemiplegia 12.4
23 spastic paraplegia 43, autosomal recessive 12.4
24 spastic paraplegia 10, autosomal dominant 12.4
25 spastic paraplegia 56, autosomal recessive 12.4
26 spastic quadriplegia 12.4
27 spastic paraplegia, optic atrophy, and neuropathy 12.4
28 spastic paraplegia 8, autosomal dominant 12.4
29 spastic paraplegia 48, autosomal recessive 12.4
30 spastic diplegia 12.4
31 spastic paraplegia 28, autosomal recessive 12.4
32 spastic paraplegia 26, autosomal recessive 12.4
33 spastic paraplegia 23 12.4
34 spastic paraplegia 35, autosomal recessive 12.4
35 spastic paraplegia 63, autosomal recessive 12.4
36 spastic paraplegia 72, autosomal recessive 12.3
37 spastic paraplegia 54, autosomal recessive 12.3
38 spastic cerebral palsy 12.3
39 spastic paraplegia 9a, autosomal dominant 12.3
40 spastic paraplegia 39, autosomal recessive 12.3
41 spastic paraplegia 11 12.3
42 spastic paraplegia 5a 12.3
43 spastic paraplegia 4 12.3
44 spastic paraplegia 15 12.3
45 spastic paraplegia 53, autosomal recessive 12.3
46 spastic paraplegia 5a, autosomal recessive 12.3
47 spastic paraplegia 6, autosomal dominant 12.3
48 infantile-onset ascending hereditary spastic paralysis 12.3
49 spastic paraplegia 45, autosomal recessive 12.3
50 spastic paraplegia 57, autosomal recessive 12.3

Graphical network of the top 20 diseases related to Spasticity:



Diseases related to Spasticity

Symptoms & Phenotypes for Spasticity

Drugs & Therapeutics for Spasticity

Drugs for Spasticity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 319)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
2
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
3
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
4
gamma-Aminobutyric acid Approved, Investigational Phase 4,Not Applicable 56-12-2 119
5
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
6
Levodopa Approved Phase 4 59-92-7 6047
7
Baclofen Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1134-47-0 2284
8
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
9
Tizanidine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51322-75-9 5487
10
Peppermint oil Approved, Investigational Phase 4,Phase 3 8006-90-4
11
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078
12
Peppermint Approved Phase 4,Phase 3
13 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
14
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
15
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
16
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
17
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
18
Fosfomycin Approved Phase 4 23155-02-4 446987
19
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
20
Sulfamethoxazole Approved Phase 4 723-46-6 5329
21
Norepinephrine Approved Phase 4 51-41-2 439260
22
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
23
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable,Early Phase 1 137-58-6 3676
24 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
25 Acetylcholine Release Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 incobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
34 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2
36 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
37 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antiparkinson Agents Phase 4,Phase 1,Not Applicable
40 calcium channel blockers Phase 4,Phase 3,Not Applicable
41 Anti-Infective Agents, Local Phase 4,Phase 3,Not Applicable
42 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Not Applicable
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Excitatory Amino Acids Phase 4,Phase 2,Not Applicable
46 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antimanic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Liver Extracts Phase 4

Interventional clinical trials:

(show top 50) (show all 883)
# Name Status NCT ID Phase Drugs
1 Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity Unknown status NCT02757404 Phase 4
2 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
3 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
4 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
5 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
6 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
7 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
8 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
9 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
10 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
11 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
12 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
13 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression Completed NCT02321436 Phase 4 BotulinumtoxinA;Placebo
14 SISTERS: Spasticity In Stroke Study - Randomized Study Completed NCT01032239 Phase 4 intrathecal baclofen
15 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
16 Vanderbilt University Spasticity Management Program Evaluation Plan Completed NCT00179114 Phase 4 Botulinum Toxin Type A;Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
17 Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity Completed NCT00234546 Phase 4 Botulinum toxin type A (Dysport®)
18 Memantine for Spasticity in MS Patients Completed NCT00638027 Phase 4 placebo;memantine
19 Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot Completed NCT03044080 Phase 4 IncobotulinumtoxinA;OnabotulinumtoxinA
20 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®
21 BOTOX® Economic Spasticity Trial (BEST) Completed NCT00549783 Phase 4
22 Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm Completed NCT00216411 Phase 4 Botulinum type A toxin (Dysport)
23 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
24 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
25 Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation-pilot Study Completed NCT03549975 Phase 4 Botulinum Toxin Type A 100 unit/Vial (Product)
26 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
27 Botulinum Toxin A Adult Gastrocnemius Muscle Study Completed NCT01278576 Phase 4 BOTOX-A®
28 Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC) Completed NCT02969356 Phase 4 AbobotulinumtoxinA (Dysport®)
29 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
30 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
31 Τhe Effectiveness of Hydrotherapy Exercises on the Rehabilitation of Hemiplegic Patients Completed NCT01460277 Phase 4
32 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
33 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
34 Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy Completed NCT02725359 Phase 4 Placebo;Tizanidine;Bupivacaine;Saline
35 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
36 Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
37 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
38 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
39 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
40 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
41 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings Recruiting NCT03302741 Phase 4 Botulinum neurotoxin (BTX)
42 Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment Recruiting NCT02462317 Phase 4 botulinum A toxin;Baclofen;Placebo toxin;placebo baclofen
43 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Recruiting NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
44 The Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke Recruiting NCT02944929 Phase 4
45 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination Recruiting NCT03367429 Phase 4 Botox
46 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
47 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
48 Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox) Not yet recruiting NCT02888548 Phase 4
49 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Terminated NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
50 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4

Search NIH Clinical Center for Spasticity

Genetic Tests for Spasticity

Genetic tests related to Spasticity:

# Genetic test Affiliating Genes
1 Spasticity 29

Anatomical Context for Spasticity

MalaCards organs/tissues related to Spasticity:

41
Spinal Cord, Brain, Testes, Skeletal Muscle, Bone, T Cells, Lung

Publications for Spasticity

Articles related to Spasticity:

(show top 50) (show all 1378)
# Title Authors Year
1
Optimizing the management of spasticity in people with spinal cord damage: a clinical care pathway for assessment and treatment decision-making from the Ability Network, an international initiative. ( 29428347 )
2018
2
O 026 - Negative impact of muscle weakness and spasticity on gait in children with unilateral cerebral palsy. ( 29954655 )
2018
3
Ultrasound Strain Imaging to Assess the Biceps Brachii Muscle in Chronic Poststroke Spasticity. ( 29399851 )
2018
4
Title: Quantifying the change of spasticity after intrathecal baclofen administration: A descriptive retrospective analysis. ( 29913361 )
2018
5
Phenol neurolysis for management of shoulder spasticity in early recovery from traumatic brain injury - a case report. ( 29933094 )
2018
6
Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. ( 29449262 )
2018
7
Dynamic spasticity determines hamstring length and knee flexion angle during gait in children with spastic cerebral palsy. ( 29960141 )
2018
8
Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. ( 29423615 )
2018
9
Quantitative Evaluation of Post-stroke Spasticity Using Neurophysiological and Radiological Tools: A Pilot Study. ( 29961736 )
2018
10
Generating the Visual Biofeedback Signals Applicable to Reduction of Wrist Spasticity: A Pilot Study on Stroke Patients. ( 29942436 )
2018
11
Effectiveness of Faradic and Russian currents on plantar flexor muscle spasticity, ankle motor recovery, and functional gait in stroke patients. ( 29417699 )
2018
12
Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study. ( 29904191 )
2018
13
Impact of spasticity on transfers and activities of daily living in individuals with spinal cord injury. ( 29334339 )
2018
14
Assessment of Spasticity by a Pendulum Test in SCI Patients Who Exercise FES Cycling or Receive Only Conventional Therapy. ( 29324409 )
2018
15
Early AbobotulinumtoxinA (Dysport<sup>Ar</sup>) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. ( 29933562 )
2018
16
The dosage and administration of long-term intrathecal baclofen therapy for severe spasticity of spinal origin. ( 29895878 )
2018
17
Comparison of Single-Session Dose Response Effects of Whole Body Vibration on Spasticity and Walking Speed in Persons with Spinal Cord Injury. ( 29959653 )
2018
18
Quantitative Ultrasound Imaging to Assess the Biceps Brachii Muscle in Chronic Post-Stroke Spasticity: Preliminary Observation. ( 29398131 )
2018
19
Supplemental Stimulation Improves Swing Phase Kinematics During Exoskeleton Assisted Gait of SCI Subjects With Severe Muscle Spasticity. ( 29910710 )
2018
20
Path analysis of strength, spasticity, gross motor function, and health-related quality of life in children with spastic cerebral palsy. ( 29673348 )
2018
21
The experience of spasticity after spinal cord injury: perceived characteristics and impact on daily life. ( 29339776 )
2018
22
Catgut implantation at acupoints increases the expression of glutamate aspartate transporter and glial glutamate transporter-1 in the brain of rats with spasticity after stroke. ( 29926828 )
2018
23
Comments on &amp;quot;Transcutaneous electrical nerve stimulation improves walking capacity and reduces spasticity in stroke survivors: a systematic review and meta-analysis&amp;quot;. ( 29376421 )
2018
24
Association of Early-Onset Spasticity and Risk for Cognitive Impairment With Mutations at Amino Acid 499 in SPAST. ( 29421991 )
2018
25
The effects of different injection techniques of botulinum toxin a in post-stroke patients with plantar flexor spasticity. ( 29978276 )
2018
26
Transcranial and spinal cord magnetic stimulation in treatment of spasticity: a literature review and meta-analysis. ( 28004906 )
2018
27
OnabotulinumtoxinA for the Treatment of Post-Stroke Distal Lower-Limb Spasticity: A Randomized Trial. ( 29330071 )
2018
28
Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients; an observational study. ( 29422486 )
2018
29
Spasticity ( 29939646 )
2018
30
Selective peripheral neurolysis using high frequency ultrasound imaging: a novel approach in the treatment of spasticity. ( 29898589 )
2018
31
The clinical assessment of spasticity in people with spinal cord damage: recommendations from the Ability Network, an international initiative. ( 29432722 )
2018
32
Botulinum Toxin-A Injection in the Treatment of Spasticity in a Infantile-Onset Neurodegeneration With Brain Iron Accumulation: A Case Report. ( 29765892 )
2018
33
C-terminal proline deletions in KCNC3 cause delayed channel inactivation and an adult-onset progressive SCA13 with spasticity. ( 29949095 )
2018
34
Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( 29326296 )
2018
35
Mild Intrauterine Hypoperfusion Leads to Lumbar and Cortical Hyperexcitability, Spasticity, and Muscle Dysfunctions in Rats: Implications for Prematurity. ( 29973904 )
2018
36
Effects of treadmill training combined with serotonergic interventions on spasticity after contusive spinal cord injury. ( 29336209 )
2018
37
Treatment with Botulinum Toxin for Refractory Fever Caused by Severe Spasticity: A Case Series. ( 29383493 )
2018
38
Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective. ( 29915932 )
2018
39
A spasticity model based on feedback from muscle force explains muscle activity during passive stretches and gait in children with cerebral palsy. ( 30532154 )
2018
40
Influence of Spinal Manipulation on Muscle Spasticity and Manual Dexterity in Participants With Cerebral Palsy: Randomized Controlled Trial. ( 30228805 )
2018
41
The Root-Ely Modified Test of Rectus Femoris Spasticity Has Reliability in Individuals with Cerebral Palsy. ( 29983655 )
2018
42
Physiological responses during clinical spasticity evaluation in elbow flexors in children with cerebral palsy. ( 30028217 )
2018
43
Spasticity in adults with cerebral palsy and multiple sclerosis measured by objective clinically applicable technique. ( 30053672 )
2018
44
Effectiveness of multiple botulinum toxin sessions and the duration of effects in spasticity therapy in children with cerebral palsy. ( 30058050 )
2018
45
Effects of a hippotherapy intervention on muscle spasticity in children with cerebral palsy: A randomized controlled trial. ( 29705454 )
2018
46
A novel sensor-based assessment of lower limb spasticity in children with cerebral palsy. ( 29866177 )
2018
47
Spasticity in children with cerebral palsy: what are we treating? ( 29624670 )
2018
48
Ultrasonographic evaluation of changes in the muscle architecture of the gastrocnemius with botulinum toxin treatment for lower extremity spasticity in children with cerebral palsy. ( 29146092 )
2018
49
Number of Synergies Is Dependent on Spasticity and Gait Kinetics in Children With Cerebral Palsy. ( 29252834 )
2018
50
Commentary on "Number of Synergies Is Dependent on Spasticity and Gait Kinetics in Children With Cerebral Palsy". ( 29252835 )
2018

Variations for Spasticity

ClinVar genetic disease variations for Spasticity:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 REEP1 NM_001164731.1(REEP1): c.524A> G (p.Ter175Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs587781248 GRCh38 Chromosome 2, 86217101: 86217101
2 REEP1 NM_001164731.1(REEP1): c.524A> G (p.Ter175Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs587781248 GRCh37 Chromosome 2, 86444224: 86444224
3 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh37 Chromosome 15, 90193067: 90193067
4 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh38 Chromosome 15, 89649836: 89649836
5 PMP22 NM_000304.3(PMP22): c.422T> G (p.Val141Gly) single nucleotide variant Uncertain significance rs1057518804 GRCh37 Chromosome 17, 15134295: 15134295
6 PMP22 NM_000304.3(PMP22): c.422T> G (p.Val141Gly) single nucleotide variant Uncertain significance rs1057518804 GRCh38 Chromosome 17, 15230978: 15230978
7 SPAST NM_014946.3(SPAST): c.1276C> T (p.Leu426Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs1060502227 GRCh37 Chromosome 2, 32361662: 32361662
8 SPAST NM_014946.3(SPAST): c.1276C> T (p.Leu426Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs1060502227 GRCh38 Chromosome 2, 32136593: 32136593
9 CREBBP NM_004380.2(CREBBP): c.6185_6195delTCTCACCCAGC (p.Ile2062Serfs) deletion Likely pathogenic GRCh37 Chromosome 16, 3778853: 3778863
10 CREBBP NM_004380.2(CREBBP): c.6185_6195delTCTCACCCAGC (p.Ile2062Serfs) deletion Likely pathogenic GRCh38 Chromosome 16, 3728852: 3728862

Expression for Spasticity

Search GEO for disease gene expression data for Spasticity.

Pathways for Spasticity

GO Terms for Spasticity

Cellular components related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.56 ATP6AP2 CAPN1 DARS PCDH12 PLAA SLC1A4
2 axon cytoplasm GO:1904115 8.8 KIF1A SPAST SPG7

Biological processes related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anterograde axonal transport GO:0008089 8.8 KIF1A SPAST SPG7

Sources for Spasticity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....